NewGenIvf Group Ltd
NewGenIvf provides fertility treatments and related services to couples and individuals seeking to build families, with clinics in Thailand, Cambodia and Kyrgyzstan. Its services include in vitro fertilization (IVF), including conventional IVF, intracytoplasmic sperm injection and embryo transfer; egg donation in Cambodia; and fertility referral services in Kyrgyzstan. It also offers egg freezing and fertility support services. MicroSort technology supports sperm sorting for gender selection and screening related to certain hereditary diseases. NewGenIvf earns money from IVF treatment services and commissions for referring customers to independent agents that provide surrogacy services in Kyrgyzstan. It also provides fertility-related technologies and services, including genetic screening and diagnosis alongside IVF. As of December 31, 2025, NewGenIvf has an accounting and general administrative support office in Hong Kong and clinics in Thailand, Cambodia and Kyrgyzstan. Its Thailand clinic is in central Bangkok.
No enriched coverage for $NIVF in the last 7 days.
No SEC Form 4 filings for $NIVF in the last 30 days.
See all $NIVF insider activity →NewGenIvf (NIVF) reported 1H GAAP EPS of -$26.64, missing estimates by $44.82. Revenue was $1.92M, down 4.5% Y/Y and $18.18M below expectations. The company also announced a $1.25M public offering of shares and pre-funded warrants.
NewGen IVF (NIVF) rose 25% after a $1.25M share offering. SeaStar Medical (ICU) gained 23% on regulatory updates. Atara Biotherapeutics (ATRA) climbed 11% with a BLA resubmission. Indaptus Therapeutics (INDP) increased 9% without specific news. All stocks traded higher on Friday.
NewGenIvf Group (NASDAQ:NIVF) shares rose 28.51% to $0.13 in after-hours trading after closing a public offering, raising $1.25M before fees. The offering included 17.85M Class A shares and pre-funded warrants at $0.07 per share and $0.06999 per warrant. The company's market cap is approximately $209,870, with a 52-week range of $1.539 to $0.06.
Recent NIVF coverage spans earnings, corporate actions and financial news.
Earnings miss suggests downward pressure on the stock.
Capital raise provides cash for debt restructuring and growth initiatives.
The fresh capital raise is expected to support operations and may sustain short‑term buying pressure.
Offering dilution and low price pressure the stock.
The modest raise adds cash but increases share count, likely causing slight downward pressure on the stock.
AlphAI scores every news story that mentions NIVF with an AI model for sentiment and relevance, and aggregates insider trades from NewGenIvf Group Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
NewGenIvf (NIVF) reported 1H GAAP EPS of -$26.64, missing estimates by $44.82. Revenue was $1.92M, down 4.5% Y/Y and $18.18M below expectations. The company also announced a $1.25M public offering of shares and pre-funded warrants.
NewGen IVF (NIVF) rose 25% after a $1.25M share offering. SeaStar Medical (ICU) gained 23% on regulatory updates. Atara Biotherapeutics (ATRA) climbed 11% with a BLA resubmission. Indaptus Therapeutics (INDP) increased 9% without specific news. All stocks traded higher on Friday.
NewGenIvf Group (NASDAQ:NIVF) shares rose 28.51% to $0.13 in after-hours trading after closing a public offering, raising $1.25M before fees. The offering included 17.85M Class A shares and pre-funded warrants at $0.07 per share and $0.06999 per warrant. The company's market cap is approximately $209,870, with a 52-week range of $1.539 to $0.06.
U.S. stocks fell Thursday, with the Dow Jones dropping 200 points. Micron (MU) reported Q4 revenue of $54.23B, beating estimates. Nexalin (NXL) and Stablecoin (SDEV) shares surged, while Corteva (CTVA) and NewGenIvf (NIVF) shares declined. Oil and gold prices rose, while European and Asian markets closed mixed.
NewGenIvf Group (NIVF) closed a $1.25 million public offering, issuing 17.86 million Class A shares and pre-funded warrants at $0.07 and $0.07 each. Proceeds will fund investments, debt restructuring, and working capital. Aegis Capital Corp. acted as placement agent.
Dow Jones fell 100 points, while Carnival (CCL) reported Q3 earnings of $1.43 per share, beating estimates. NASDAQ and S&P 500 also saw mixed trading. BIO-Key (BKYI) and SoundThinking (SSTI) shares surged on strategic news. NewGenIvf (NIVF) and Triller (ILLR) shares dropped significantly.
Biotech stocks SLXN and SMMT rose premarket. SLXN gained on positive preclinical data, while SMMT jumped after a $2B equity investment from AZN. NIVF and QURE declined.
On September 2, 2026, insiders made notable stock purchases. AURA MINERALS INC. ($AUGO) insider Bruno Sousa Mauad bought 126,000 shares for $11.26M. NEWGENIVF GROUP LTD ($NIVF) insider Cheung Kong Yiu purchased 2.5M shares for $2.5M. EMPERY DIGITAL INC. ($EMPD) insider Empery Asset Management, LP bought 500,000 shares for $1.79M. VISTRA CORP. ($VST) CEO James A. Burke acquired 4,465 shares for $603,891. LIBERTY LATIN AMERICA LTD. ($LILA) insider John C. Malone bought 69,454 shares for $590,310.
Cheung Kong Yiu purchased 3,722,223 shares of NewGenIvf Group Ltd (NIVF) at an average of $1.12 ($1.00–$1.50, $4.16M total) across 4 trades over 2026-05-28 to 2026-07-27.
NewGenIvf Group (NIVF) said it agreed to buy an additional 3% equity stake in K25.ai for $250 million, raising its total ownership to 13%. The deal is expected to issue about 2.5 million Class A ordinary shares. NIVF was indicated at $1.07 in pre-market, down 4.46% on Nasdaq.
